|Description||Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. It exhibits potential antiangiogenic and antineoplastic activities.|
|B0084-262244||500 mg||$279||In stock|
|Brife Description||inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β|
|Synonyms||Vargatef; BIBF-1120; BIBF 1120; Intedanib|
|Solubility||Water: 9.66 mg/L|
|Application||the treatment of idiopathic pulmonary fibrosis|
SSR128129E free acid
SSR128129E free acid is a multi-FGFR blocker with allosteric properties. It inhibits FGFR signaling by binding to the extracellular FGFR domain without affectin...
BLU9931 is a potent and irreversible small-molecule inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 si...
SKLB610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth...
BIBF 1120 esylate
Nintedanib esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
Debio-1347, also known as FF284 and CH5183284, is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and ...
LY2874455 exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activit...
This active molecular is a Axl receptor tyrosine kinase inhibitor, Proto oncogene protein c met inhibitor, Type-1, Type-2 and Type-3 fibroblast growth factor re...
NSC12 is an extracellular trap for fibroblast growth factor 2 (FGF2). It binds FGF2 with Kd value of 51 µM and interferes with its interaction with FGFR1 withou...
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59...
AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. AZD4547 binds to and inhibi...
FIIN-2 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor. FIIN-2 is the first inhibitor that can potently inhibit the prolife...
FGF-401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4) (IC50= 1.9 nM) developed for the treatment of solid tumor.
PD173074 is a small-molecule FGFR3-selective tyrosine kinase inhibitor (TKI), as a therapeutic modality using eight UC cell lines. PD173074 suppressed cell prol...
ARQ-087, also known as Derazantinib, is an oral fibroblast growth factor receptor (FGFR) inhibitor with antitumor property. FGFR plays a role in the regulation ...
ACTB-1003 is an oral kinase inhibitor with multiple modes of action, targeting cancer mutations via FGFR inhibition FGFR1, angiogenesis through inhibition of VE...
H3B-6527 is a potent, highly selective and orally active FGFR4 inhibitor with potential antineoplastic activity.
BGJ398, also known as NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs...
Dovitinib, also referred as CHIR-258 or TKI258, is a potent receptor tyrosine kinase inhibitor (TKI) that selectively targets VEGFR, PDGFR, FGFR, CSF1R, c-KIT, ...
FGFR4-IN-1 is a potent and selective FGFR4 inhibitor with potential for the treatment of gastric cancer.
PD-161570 is a selective inhibitor of human FGF-1 receptor tyrosine kinase, with IC50 values to be 40, 262 and 3700 nM for FGFR1, PDGFR and EGFR tyrosine kinase...